EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Economic evaluation of an adjunctive intraocular and peri-ocular steroid vitreoretinal surgery for open globe trauma: Cost-effectiveness of the ASCOT randomised controlled trial

Victory 'Segun Ezeofor iD, Bethany F Anthony, Lucy Bryning, Edward J Casswell, Suzie Cro, Victoria R Cornelius, Catey Bunce, Elizabeth Robertson, Joanna Kelly, Caroline Murphy, Philip J Banerjee, David G Charteris und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311158 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Victory 'Segun Ezeofor und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Economics & Medicines Evaluation, Bangor University, Bangor, Wales. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Quality-Adjusted Life Years, Eye Injuries, Vitreoretinal Surgery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment Programme, Health and Care Research Wales.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the United Kingdom, it is estimated that 5,000 patients sustain eye injuries or ocular trauma requiring hospital admission annually, of which 250 patients will be permanently blinded. This study explores the cost-effectiveness of Adjunctive Steroid Combination in Ocular Trauma (ASCOT) given during surgery versus standard treatment in vitreoretinal surgery in patients with open globe trauma.

Methods

This economic evaluation was embedded alongside the ASCOT RCT (ClinicalTrials.gov Identifier: NCT02873026). We conducted a primary cost-effectiveness analysis from a National Health Service perspective using the proportion of patients who achieved a visual acuity of 10 or more letter improvement on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale as the measure of effect, in developing incremental cost-effectiveness ratios (ICERs). Secondary cost-utility analysis using the EuroQol 5 Dimension 5 Level (EQ-5D-5L) to generate a cost per quality-adjusted life-year (QALY), and a cost-effectiveness analysis using vision-specific quality of life (QoL) was conducted. Sensitivity analyses were also applied to investigate parameter uncertainties.

Results

The sample size of the ASCOT intervention arm and standard care arm of this study was 130 and 129, respectively. The intervention cost per patient was estimated at £132. The proportion of participants with an ETDRS of 10 or more letter improvement was 0.47 for the ASCOT group with a mean cost of £5,526 per patient, while the standard care group had an effect of 0.43 with a mean cost of £5,099 per patient. The ICER value of the primary outcome was £12,178 per 10 or more letter improvement on the ETDRS score. The secondary result in terms of cost per QALYs gained had a probability of 44% being cost-effective at a willingness-to-pay threshold of £30,000/QALY gained.

Conclusions

Though there is no formally accepted cost-effectiveness willingness-to-pay threshold for 10-letter or more improvement, the ASCOT intervention for open globe trauma is a low-cost intervention. The ASCOT intervention is not cost-effective when compared to the standard care in this group and setting. The proportion of patients in the ASCOT intervention arm with 10 or more letter improvement produced some positive results but this is outweighed by the costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisQuality-Adjusted Life YearsEye InjuriesVitreoretinal SurgeryHumansMaleFemaleMiddle AgedAdultUnited KingdomVisual AcuityQuality of Life

Autor:innen und Institutionen

  • Centre for Health Economics & Medicines Evaluation, Bangor University, Bangor, Wales.
  • Vitreoretinal Department, Moorfields Eye Hospital, London, United Kingdom.
  • Imperial Clinical Trials Unit, Imperial College London, London, United Kingdom.
  • Royal Marsden Clinical Trials Unit, Royal Marsden Hospital, National Health Service Trust, London, United Kingdom.
  • King's Clinical Trials Unit, King's College London, London, United Kingdom.

ORCID-Profile: Victory 'Segun Ezeofor

Förderung

  • Health Technology Assessment Programme
  • Health and Care Research Wales

Zitieren

APA

Ezeofor, V., Anthony, B. F., Bryning, L., Casswell, E. J., Cro, S., Cornelius, V. R., Bunce, C., Robertson, E., Kelly, J., Murphy, C., Banerjee, P. J., Charteris, D. G., & Edwards, R. T. (2024). Economic evaluation of an adjunctive intraocular and peri-ocular steroid vitreoretinal surgery for open globe trauma: Cost-effectiveness of the ASCOT randomised controlled trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0311158

Vancouver

Ezeofor V, Anthony BF, Bryning L, Casswell EJ, Cro S, Cornelius VR, et al. Economic evaluation of an adjunctive intraocular and peri-ocular steroid vitreoretinal surgery for open globe trauma: Cost-effectiveness of the ASCOT randomised controlled trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0311158

BibTeX
@article{Ezeofor2024,
  author = {Ezeofor, Victory 'Segun and Anthony, Bethany F and Bryning, Lucy and Casswell, Edward J and Cro, Suzie and Cornelius, Victoria R and Bunce, Catey and Robertson, Elizabeth and Kelly, Joanna and Murphy, Caroline and Banerjee, Philip J and Charteris, David G and Edwards, Rhiannon Tudor},
  title = {Economic evaluation of an adjunctive intraocular and peri-ocular steroid vitreoretinal surgery for open globe trauma: Cost-effectiveness of the ASCOT randomised controlled trial},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311158}
}
Kostenlos starten →